ArticleFrontiers in oncology2026
Clinicopathological features of adult lymphoblastic lymphoma: a retrospective multicenter study from Türkiye.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lymphoblastic lymphoma (LBL) is a highly aggressive malignancy composed of immature lymphocytes of B- cell or T-cell origin. LBL is typically distinguished from acute lymphoblastic leukemia (ALL) by the presence of fewer than 20% bone marrow blasts. This retrospective multicenter cohort study evaluated the clinical data of adult LBL patients diagnosed and treated at tertiary centers in Türkiye. Materials and methods: Thirty-eight patients from seven tertiary adult hematology clinics were included. Eligible patients were ≥18 years of age, had a pathologically confirmed diagnosis of LBL, underwent radiological staging, and received at least one chemotherapy regimen. Results: The median overall survival (OS) for the entire cohort was 23 months. No statistically significant difference in OS was observed between patients with T-LBL and those with B-LBL (p>0.05). The median progression-free survival (PFS) was 6 months. The 5-year OS rate was 6%, underscoring the aggressive nature of adult LBL. Discussion: Our findings
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.